← Library
Liraglutide
FDA ApprovedSince 2010
Also known as Victoza, Saxenda
Function
Primary
Type 2 Diabetes · Obesity
Secondary
CV mortality reduction
Mechanism
GLP-1 receptor agonist — daily insulin secretion and appetite suppression; demonstrated CV mortality reduction (LEADER).
Evidence
Clinical RCT (Phase III)
Research
Phase III LEADER / SCALE programs
Dosing
Range
0.6–1.8 mg/day (DM); up to 3 mg/day (obesity)
Frequency
Daily
Route
Subcutaneous
Cycling
Continuous; weekly dose titration.
Benefits
- ·Weight reduction 5–10%
- ·CV mortality reduction in T2D + CV disease
- ·Glycemic control
Risks
- ·Thyroid C-cell tumor risk
- ·Pancreatitis
- ·Heart rate increase
- ·Gallbladder disease
Contraindications
- ·MTC / MEN-2
- ·Pregnancy
Regulatory
FDA-Approved Rx
Functional Groups
Cited Works
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375:311.source